183 related articles for article (PubMed ID: 25389607)
1. Intravitreal bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization overlying choroidal osteoma.
Shields CL; Salazar PF; Demirci H; Benson WE; Shields JA
Retin Cases Brief Rep; 2008; 2(1):18-20. PubMed ID: 25389607
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of choroidal neovascularization complicating a choroidal osteoma with intravitreal bevacizumab.
Rao S; Gentile RC
Retin Cases Brief Rep; 2010; 4(4):303-5. PubMed ID: 25390904
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab and ranibizumab for choroidal neovascularization secondary to endogenous endophthalmitis.
Fecko AM; Ho LY; Walsh MK; Williams GA
Retin Cases Brief Rep; 2011; 5(3):229-32. PubMed ID: 25390171
[TBL] [Abstract][Full Text] [Related]
4. Functional and anatomical outcomes for intravitreal bevacizumab treatment of choroidal neovascularization in a patient with angioid streaks.
Garcia RA; Jablon EP; Oria V; Rodriguez-Fontal M; Alfaro DV; Parikh NS
Retin Cases Brief Rep; 2008; 2(2):136-40. PubMed ID: 25389825
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration.
Bhatnagar P; Spaide RF; Takahashi BS; Peragallo JH; Freund KB; Klancnik JM; Cooney MJ; Slakter JS; Sorenson JA; Yannuzzi LA
Retina; 2007 Sep; 27(7):846-50. PubMed ID: 17891007
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.
Fine HF; Zhitomirsky I; Freund KB; Barile GR; Shirkey BL; Samson CM; Yannuzzi LA
Retina; 2009 Jan; 29(1):8-12. PubMed ID: 18784620
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (avastin) for choroidal neovascularization associated with deferoxamine retinopathy.
Duval R; Olivier S
Retin Cases Brief Rep; 2011; 5(3):233-6. PubMed ID: 25390172
[TBL] [Abstract][Full Text] [Related]
8. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
9. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
10. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.
Nielsen JS; Fick TA; Saggau DD; Barnes CH
Retina; 2012 Mar; 32(3):468-72. PubMed ID: 21817958
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma.
Yoshikawa T; Takahashi K
Clin Ophthalmol; 2015; 9():429-37. PubMed ID: 25784788
[TBL] [Abstract][Full Text] [Related]
14. [Intravitreal injection of bevacizumab for CNV secondary to choroidal osteoma and follow-up by Spectral-Domain OCT].
Mercé E; Korobelnik JF; Delyfer MN; Rougier MB
J Fr Ophtalmol; 2012 Sep; 35(7):508-13. PubMed ID: 22695057
[TBL] [Abstract][Full Text] [Related]
15. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study].
Baeteman C; Hoffart L; Galland F; Ridings B; Conrath J
J Fr Ophtalmol; 2009 May; 32(5):309-13. PubMed ID: 19769866
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of the choroidal neovascular membrane by ranibizumab (Lucentis): a case report].
Nemec P; Benesová Z; Hejsek L
Cesk Slov Oftalmol; 2010 Jul; 66(3):134-7. PubMed ID: 21137476
[TBL] [Abstract][Full Text] [Related]
18. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
20. Anti-vascular endothelial growth factors for choroidal neovascularization secondary to choroidal osteoma: Long-term results.
Lekha T; Renuka NS; Prasad HN
Oman J Ophthalmol; 2015; 8(3):185-7. PubMed ID: 26903728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
